MGTX News & Analysis
3 articles
Market Mood
Goldman Sachs Initiates MeiraGTx Coverage with Neutral Rating
Goldman Sachs has started coverage of MeiraGTx Holdings PLC with a neutral rating. This new rating indicates an assessment of the stock that does not favor either buying or selling. By providing this coverage, Goldman Sachs is aligning its investment stance with a balanced perspective on MeiraGTx's future performance. Investors should note that this neutral rating means there may not be significant changes expected in the stock's price in the near term.
Read More: Goldman Sachs Initiates MeiraGTx Coverage with Neutral Rating
MeiraGTx (MGTX) Insider Sold 27,659 Shares at $14.80 Each
Stuart Naylor, Chief Scientific Officer of MeiraGTx Holdings plc (MGTX), sold 27,659 shares on July 7, 2026, with prices ranging from $13.36 to $15.33, averaging $14.80 per share. This sale, representing a 4% reduction in his holdings, aligns with a pre-scheduled Rule 10b5-1 trading plan. Naylor retains 641,000 shares, valued at $9.39 million based on the closing price of $14.66. MeiraGTx has seen a 89% stock appreciation over the past year, indicating strong investor confidence, which is crucial for market sentiment regarding biotech investments.
Read More: MeiraGTx (MGTX) Insider Sold 27,659 Shares at $14.80 Each
MeiraGTx Holdings (MGTX) Reaches 52-Week High at 13.72 USD
MeiraGTx Holdings (MGTX) reached a 52-week high of 13.72 USD. This milestone reflects a significant price movement for the stock, indicating positive market sentiment. The achievement of this high is relevant as it may influence investor confidence and trading activity. Continued upward movement could lead to increased investment interest in MGTX, impacting its market position.
Read More: MeiraGTx Holdings (MGTX) Reaches 52-Week High at 13.72 USD